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Lay Summary. Many clinically useful drugs act by binding to DNA, 
the genetic material. This family of drugs includes antiviral, 
antifungal, antitrypanosomal and especially anticancer agents. For 
exar:nple both adriamycin (used to treat solid tumors) and daunomycin 
(used to treat leukemia) bind to DNA. These drugs ultimately i nte rfe re 
with cellular machinery by which cells copy and process their DNA. The 
goal of our research is to understand, and to someday even predict, how 
these drugs bind to, and distort DNA.. We are trying to address these 
issues on an extremely detailed levet, by actually looking at the exact 
positions of individual atoms of DNA-drug complexes. To do this we 
use a technique known as x-ray crystallography. We grow crystals of 
DNA-drug complexes (not an easy process) and direct a beam of x-rays 
through the crystal. The beam of x-rays is scattered by the atoms of 
the crystal. By collecting and properly proce~ssing the scattered x-ray 
beam we can reconstruct the positions of thH atoms of the DNA and of 
the bound drug molecule. The information we obtain is used to design 
new and better chemotherapeutic agents. 
Scientific Summary. Our ultin1ate goal is structure-based drug 
design of DNA-binding anticancer chemothe!rapeutics. Structure-
based drug design entails ( 1) detailed! 3-D structures and analysis of 
inhibited complexes of target macrornolecules, (2) solution affinity 
measurements, (3) biological screeniing, and (4) design and syntheses 
of new inhibitors. 
DNA is a target of many clinically important chemotherapeutic 
agents. DNA-binding antibiotic, antiviral, antitrypanasomal and 
anticancer agents can inhibit or disrupt such processes as DNA 
replication, transcription and topoisomerase activities. 
Che.motherapeutic agents bind to DNA within the grooves, ordinarily 
within the minor rather than the major groove, and/or by 
intercalating between the bases. Examples of clinically important 
intercalating-minor groove binders are daunomycin and the closely 
related adriamycin, currently two of the most widely used 
anticancer chemotherapeutic agents. However as a target for design 
of new chemotherapeutic agents, DNA offers special problems. 
Crystallography of DNA and its complexes is much less developed 
than that of proteins. The longest fragment of DNA solved by single 
crystal X-ray diffraction is less than 20 residues. In addition, 
modeling is difficult. With every residue in contact with aqueous 
solvent, the interface is much morE~ extensive than with a globular 
protein. Modeling is further complicated by the high formal charge 
of DNA. Finally, the conformation of DNA is much more mutable than 
that of most protein targets. DNA conformation is highly dependent 
on that of the inhibitor. However, 'With the approaches described 
here, including our collaborations with groups in Paris and at 
Rutgers, we believe that the future prospects for this approach are 
encouraging. 
